



INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

By: Philippe L. Durette

Attorney _____ For Applicant(s)

Reg. No. 35,125

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-4568

Date: January 15, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Olson, et al.

Serial No. 10/697,547

Filed: October 30, 2003

For: 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
INHIBITORS USEFUL FOR THE TREATMENT OF
DIABETES AND DYSLIPIDEMIAArt Unit: 1626Examiner: R.W. RamsuerCommissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Philippe & Carlette Date Jan. 15, 2004

(use as many sheets as necessary)

APPLICANT
JAN 23 2004
PATENT & TRADEMARK OFFICE

Sheet

2

of

2

10/697.547

October 30, 2003

Olson, et al.

Examiner Name

Attorney Docket Number

21102DA

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

G

Reimlinger et al., *Chemische Berichte*, Vol. 103, No. 6, pp. 1960-1981 (1970), "Synthesis of s-triazolo[3,4-a]isoquinolines" (full text)

Examiner

Date _____

(use as many sheets as necessary)

OFFICE
APPLICANT
JAN 20 2004
PATENT & TRADEMARK OFFICE

Application Number	10/697,547
Filing Date	October 30, 2003
First Named Inventor	Olson, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21102DA

Sheet

1

of

2

Attorney Docket Number 21102DA

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	A	PCT	WO 03/004497		SUMITOMO PHARMACEUTICALS COMPANY, LIMITED	01/16/2003
	B	PCT	WO 99/29674		JANSSEN PHARMACEUTICA N.V.	06/17/1999
	C	PCT	WO 00/07997		ABBOTT LABORATORIES	02/17/2000
	D	PCT	WO 00/07997 Corrected Version		ABBOTT LABORATORIES	02/17/2000
	E	PCT	WO 01/60802		ABBOTT LABORATORIES	08/23/2001
	F	PCT	WO 01/90094 A1		BIOVITRUM AB	11/29/2001

**Examiner
Signature**

Date
Considered